Perspectives for TNF-alpha-targeting therapies (Q34731078)

4 August 2017

12 references

13 March 2019

21 March 2019

17 June 2019

30 June 2019

1 August 2019

27 September 2019

20 November 2019

27 November 2019

13 December 2019

14 November 2020

1 February 2021

28 October 2022

Perspectives for TNF-alpha-targeting therapies (English)

1 reference

disease-modifying antirheumatic drug

4 August 2017

0 references

10 references

13 March 2019

21 March 2019

17 June 2019

30 June 2019

1 August 2019

27 September 2019

20 November 2019

27 November 2019

13 December 2019

14 November 2020

10 references

13 March 2019

21 March 2019

17 June 2019

30 June 2019

1 August 2019

27 September 2019

20 November 2019

27 November 2019

13 December 2019

14 November 2020

tumor necrosis factor

2 references

1 August 2019

1 February 2021

1 reference

27 September 2019

1 reference

20 November 2019

1 reference

27 November 2019

1 reference

13 December 2019

1 reference

14 November 2020

1

Hanns-Martin Lorenz

1 reference

4 August 2017

Joachim R Kalden

2

1 reference

4 August 2017

9 May 2002

13 references

Arthritis Research and Therapy

4 August 2017

13 March 2019

21 March 2019

17 June 2019

30 June 2019

1 August 2019

27 September 2019

20 November 2019

27 November 2019

13 December 2019

14 November 2020

1 February 2021

28 October 2022

1 reference

4 August 2017

12 references

13 March 2019

21 March 2019

17 June 2019

30 June 2019

1 August 2019

27 September 2019

20 November 2019

27 November 2019

13 December 2019

14 November 2020

1 February 2021

28 October 2022

4 Suppl 3

1 reference

4 August 2017

S17-24

1 reference

https://scigraph.springernature.com/pub.10.1186/ar564

4 August 2017

0 references

cites work

Treatment of intestinal Behçet's syndrome with chimeric tumour necrosis factor alpha antibody

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3240140

Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3240140

Remission of Behçet's syndrome with tumour necrosis factor alpha blocking therapy

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3240140

Levels of interleukin-18 and its binding inhibitors in the blood circulation of patients with adult-onset Still's disease

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3240140

Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behçet's disease: a case report

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3240140

Naturally occurring and synthetic inhibitors of NF-kappaB functions.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3240140

Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3240140

Treatment of rheumatoid arthritis with PEGylated recombinant human soluble tumour necrosis factor receptor type I: a clinical update

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3240140

Signal transduction by tumor necrosis factor and gene regulation of the inflammatory cytokine interleukin-6.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3240140

Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3240140

Macrophage-derived cytokine and nuclear factor kappaB p65 expression in synovial membrane and skin of patients with psoriatic arthritis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3240140

Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3240140

Thalidomide: current and potential clinical applications

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3240140

The majority of epidermal T cells in Psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiat

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3240140

A proinflammatory role for IL-18 in rheumatoid arthritis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3240140

Course of gut inflammation in spondylarthropathies and therapeutic consequences

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3240140

Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3240140

Effect of infliximab on sight-threatening panuveitis in Behçet's disease.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3240140

Infliximab in the treatment of adult Still's disease refractory to conventional therapy

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3240140

Etanercept combined with conventional treatment in Wegener's granulomatosis: a six-month open-label trial to evaluate safety

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3240140

A murine transmembrane tumor necrosis factor (TNF) transgene induces arthritis by cooperative p55/p75 TNF receptor signaling

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3240140

A preliminary study of etanercept in the treatment of severe, resistant psoriatic arthritis

9 December 2018

1 reference

12 December 2020

Effects of interferon-alpha2a treatment on serum levels of tumor necrosis factor-alpha, tumor necrosis factor-alpha2 receptor, interleukin-2, interleukin-2 receptor, and E-selectin in Behçet's disease

1 reference

12 December 2020

Tumor necrosis factor-alpha expression in muscles of polymyositis and dermatomyositis

1 reference

12 December 2020

Correlation between plasma TNF-alpha, IGF-1, biochemical markers of bone metabolism, markers of inflammation/disease activity, and clinical manifestations in ankylosing spondylitis

1 reference

12 December 2020

Treatment of psoriatic arthritis with antitumour necrosis factor-alpha antibody clears skin lesions of psoriasis resistant to treatment with methotrexate

1 reference

12 December 2020

Treatment of recalcitrant orogenital ulceration of Behçet's syndrome with infliximab

1 reference

12 December 2020

Allelic distribution of HLA-B*5 in HLA-B5-positive Israeli patients with Behçet's disease

1 reference

12 December 2020

In situ production of TNF-alpha, IL-1 beta and IL-2R in ANCA-positive glomerulonephritis

1 reference

12 December 2020

The Cytokine Network in Lesional and Lesion-Free Psoriatic Skin Is Characterized by a T-Helper Type 1 Cell-Mediated Response

1 reference

12 December 2020

Elevated tumour necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions

1 reference

12 December 2020

1 reference

12 December 2020

Systemic levels of the T cell regulatory cytokines IL-10 and IL-12 in Bechçet's disease; soluble TNFR-75 as a biological marker of disease activity

1 reference

12 December 2020

Expression of tumor necrosis factor-alpha in muscles of polymyositis

1 reference

12 December 2020

Elevated serum interleukin 6, interferon-gamma, and tumor necrosis factor-alpha levels in patients with adult Still's disease

1 reference

12 December 2020

Serum TNF-alpha levels correlate with disease severity and are reduced by effective therapy in plaque-type psoriasis

1 reference

12 December 2020

Active Wegener's granulomatosis is associated with HLA-DR+ CD4+ T cells exhibiting an unbalanced Th1-type T cell cytokine pattern: reversal with IL-10

1 reference

12 December 2020

Patterns of cytokine production in psoriatic synovium

1 reference

12 December 2020

TNFalpha and response of treatment-resistant adult-onset Still's disease to thalidomide

1 reference

12 December 2020

Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial

1 reference

12 December 2020

Identifiers

DOI

10.1186/AR564

1 reference

PubMed ID

12110119

Dimensions Publication ID

4 August 2017

0 references

1 reference

4 August 2017

1 reference

PubMed ID

12110119